Advertisement

PharmacoEconomics & Outcomes News

, Volume 818, Issue 1, pp 4–4 | Cite as

Add-on umeclidinium cost effective in COPD in the UK

Clinical study
  • 12 Downloads

Reference

  1. Driessen M, et al. Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. Respiratory Medicine 145: 130-137, Dec 2018. Available from: URL: http://doi.org/10.1016/j.rmed.2018.10.024 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations